The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.
Where this comes from
- Record sourced from PubMed, PMID 32704031.
- Also identified by DOI 10.1038/s41379-020-0629-6 and PMC identifier 8375585.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The publication of the "Pan-Cancer Atlas" by the Pan-Cancer Analysis of Whole Genomes Consortium, a partnership formed by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), provides a wonderful opportunity to reflect on where we stand in our understanding of the genetics of pancreatic cancer, as well as on the opportunities to translate this understanding to patient care. From germline variants that predispose to the development of pancreatic cancer, to somatic mutations that are therapeutically targetable, genetics is now providing hope, where there once was no hope, for those diagnosed with pancreatic cancer.
Medical subject headings
- Biomarkers, Tumor
- Carcinoma, Pancreatic Ductal
- Genetic Variation
- Genomics
- Molecular Diagnostic Techniques
- Pancreatic Neoplasms